Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. The company develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. Its lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. The company also markets DepoCyt(e), a liposomal formulation of the chemotherapeutic agent cytarabine indicated for the intrathecal treatment of lymphomatous meningitis, a life-threatening complication of lymphoma, a cancer of the immune system. Its development pipeline comprises DepoMeloxicam, a long-acting non-steroidal anti-inflammatory drug, which is in preclinical development for the treatment of acute postsurgical pain; and DepoTranexamic Acid, a pre-clinical development product for the treatment or prevention of excessive blood loss during surgery by promoting hemostasis. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010.

Parsippany Troy Hills, US
Size (employees)
503 (est)+4%
Pacira Pharmaceuticals was founded in 2006 and is headquartered in Parsippany-Troy Hills, US

Pacira Pharmaceuticals Office Locations

Pacira Pharmaceuticals has offices in Parsippany-Troy Hills, San Diego, New York, Jersey and in 1 other location
Parsippany Troy Hills, US (HQ)
300 5 Sylvan Way
San Diego, US
125 10578 Science Center Dr
San Diego, US
11011 N Torrey Pines Rd

Pacira Pharmaceuticals Data and Metrics

Pacira Pharmaceuticals Financial Metrics

Pacira Pharmaceuticals's revenue was reported to be $276.4 m in FY, 2016 which is a 11% increase from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

276.4 m

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

198.9 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

(37.9 m)

EBIT (FY, 2016)

(5.2 m)

Market capitalization (21-Jun-2017)

1.9 b

Closing share price (21-Jun-2017)


Cash (31-Dec-2016)

35.9 m
Pacira Pharmaceuticals's current market capitalization is $1.9 b.
FY, 2013FY, 2014FY, 2015FY, 2016


85.6 m197.7 m249 m276.4 m

Revenue growth, %


Cost of goods sold

54.8 m77.4 m71.8 m77.4 m

Gross profit

30.8 m120.2 m177.2 m198.9 m

Gross profit Margin, %


Operating expense total

138.8 m202.8 m239.5 m202.8 m


(53.3 m)(5.2 m)9.5 m(5.2 m)

EBIT margin, %


Interest expense

7.3 m8.3 m7.7 m8.3 m

Interest income

259 k382 k678 k382 k

Pre tax profit

(64.4 m)(13.5 m)2.1 m(13.5 m)

Income tax expense

442 k(173 k)(264 k)(173 k)

Net Income

(63.9 m)(13.7 m)1.9 m(37.9 m)
FY, 2013FY, 2014FY, 2015FY, 2016


12.5 m37.5 m57 m35.9 m

Accounts Receivable

14.6 m22.4 m25.9 m29.9 m


15.6 m29.3 m6.1 m9.3 m

Current Assets

106.8 m214.3 m252.6 m243.1 m


10.3 m23.8 m30.9 m46.7 m

Total Assets

169.8 m326.1 m389.6 m391.5 m

Accounts Payable

3.1 m6.8 m8.7 m7.5 m

Current Liabilities

121.9 m140 m151.7 m44.8 m

Additional Paid-in Capital

337.6 m481.3 m526.7 m565.2 m

Retained Earnings

(296.4 m)(310.1 m)(308.3 m)(346.2 m)

Total Equity

41.2 m218.4 m219 m

Financial Leverage

4.1 x1.8 x1.8 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(63.9 m)(13.7 m)1.9 m(13.7 m)

Depreciation and Amortization

5.7 m

Accounts Receivable

(10 m)(7.8 m)(3.5 m)(7.8 m)


(3.5 m)(14 m)(32 m)

Accounts Payable

10.2 m14.3 m9.9 m

Cash From Operating Activities

(43.2 m)25.5 m29 m26.6 m

Purchases of PP&E

(12.8 m)

Cash From Investing Activities

(43.6 m)(119.3 m)(20.2 m)(120.4 m)

Long-term Borrowings

(27.5 m)

Cash From Financing Activities

89.2 m118.9 m10.7 m118.9 m

Income Taxes Paid

34 k195 k34 k
Numbers are in $, USDY, 2016


567.5 k

Financial Leverage

1.8 x

Pacira Pharmaceuticals Market Value History

Pacira Pharmaceuticals Job Categories

Pacira Pharmaceuticals Company Life and Culture

You may also be interested in